Pembrolizumab (PD-1 Blocking Antibody)(Merck)은 PD-1 표적 항체로, Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 22.2% (ClinicalTrials.gov NCT02437136). PK: t½ 0.5 h. 차별점: novel, effective option.
PD-1
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Active
CAR-T cells targeting PD-L1 demonstrated strong anti-tumor effect
vedotin plus pembrolizumab in advanced urotheli
linker optimization to enhance manufacturability and reduce aggregation
humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3)
novel, effective option
checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
DNA damage on cancer cells and generates reactive oxygen species (ROS) within cells
PD-L1) positive
resistance to extreme pH, temperature, and proteolytic environments, making them especially suitable for demanding biomedical setting
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Pembrolizumab (PD-1 Blocking Antibody)(Merck)은 PD-1 표적 항체로, Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 22.2% (ClinicalTrials.gov NCT02437136). PK: t½ 0.5 h. 차별점: novel, effective option.
PD-1
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Active
CAR-T cells targeting PD-L1 demonstrated strong anti-tumor effect
vedotin plus pembrolizumab in advanced urotheli
linker optimization to enhance manufacturability and reduce aggregation
humanized monoclonal antibody (mAb) targeting lymphocyte activation gene-3 (LAG-3)
novel, effective option
checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
DNA damage on cancer cells and generates reactive oxygen species (ROS) within cells
PD-L1) positive
resistance to extreme pH, temperature, and proteolytic environments, making them especially suitable for demanding biomedical setting
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.